Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Dec;57(12):927-941.
doi: 10.1007/s00535-022-01919-y. Epub 2022 Oct 19.

Clinical practice guidelines for duodenal cancer 2021

Affiliations
Practice Guideline

Clinical practice guidelines for duodenal cancer 2021

Kenji Nakagawa et al. J Gastroenterol. 2022 Dec.

Abstract

Duodenal cancer is considered to be a small intestinal carcinoma in terms of clinicopathology. In Japan, there are no established treatment guidelines based on sufficient scientific evidence; therefore, in daily clinical practice, treatment is based on the experience of individual physicians. However, with advances in diagnostic modalities, it is anticipated that opportunities for its detection will increase in future. We developed guidelines for duodenal cancer because this disease is considered to have a high medical need from both healthcare providers and patients for appropriate management. These guidelines were developed for use in actual clinical practice for patients suspected of having non-ampullary duodenal epithelial malignancy and for patients diagnosed with non-ampullary duodenal epithelial malignancy. In this study, a practice algorithm was developed in accordance with the Minds Practice Guideline Development Manual 2017, and Clinical Questions were set for each area of epidemiology and diagnosis, endoscopic treatment, surgical treatment, and chemotherapy. A draft recommendation was developed through a literature search and systematic review, followed by a vote on the recommendations. We made decisions based on actual clinical practice such that the level of evidence would not be the sole determinant of the recommendation. This guideline is the most standard guideline as of the time of preparation. It is important to decide how to handle each case in consultation with patients and their family, the treating physician, and other medical personnel, considering the actual situation at the facility (and the characteristics of the patient).

Keywords: Clinical practice guidelines; Duodenal cancer; The Japan duodenal cancer guideline committee; Treatment.

PubMed Disclaimer

Conflict of interest statement

Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: MSD, Ono Pharmaceutical, Medical Beebe Partners, 3D Matrix, Nihon Pharmaceuticals, Fujifilm, Olympus, Tella Pharma, ICON Japan, IQVIA Services Japan, Gunze Medical Japan, Janssen Pharma, Kyorin Pharmaceutical, Covidien Japan, Sanofi, Nippon Kayaku, Johnson & Johnson, Nichi-Iko Pharmaceutical, Central Medical, Terumo, HOYA Pentax, Mitsubishi Tanabe Pharma, Tsumura & Co., EA Pharma, Astellas Pharma, Eisai, Shionogi & Co., Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Yakuhin, Yakult Honsha, AbbVie, Astra Zeneca, Eli Lilly Japan, Pfizer, Gilead Sciences, Merck Serono, Sumitomo Dainippon Pharma Co., Mediscience Planning Inc., Solasia Pharma, Parexel International Inc., and Amgen Astellas BioPharma.

Figures

Fig. 1
Fig. 1
Diagnosis algorithm of duodenal cancer. CQ clinical question
Fig. 2
Fig. 2
Treatment algorithm of resectable duodenal cancer. Although there is no evidence for additional surgery after local resection of the duodenum, a comprehensive decision an overall decision should be made whether to perform pancreato-duodenectomy plus lymph node dissection, taking into account pathological tumor and patient factors such as vascular invasion and residual cancer. Tis tumor confined to the lamina propria, SM tumor confined to the submucosa, CQ clinical question, EMR endoscopic mucosal resection, CSP cold snare polypectomy, ESD endoscopic submucosal dissection, LECS laparoscopy and endoscopy cooperative surgery, HM horizontal margin, VM vertical margin, EGD esophagogastroduodenoscopy
Fig. 3
Fig. 3
Treatment algorithm of un-resectable duodenal cancer. CQ clinical question

References

    1. Kojimahara N, Nakayama T, Morizane T, et al. Manual for Minds Clinical Practice Guideline Development 2017, Japan Council for Quality Health Care. https://minds.jcqhc.or.jp/s/developer_manual(in Japanese).
    1. Qubaiah O, Devesa S, Platz C, et al. Small intestinal cancer: a population-based study of incidence and survival patterns in the United States, 1992 to 2006. Cancer Epidemiol Biomark Prev. 2010;19:1908–1918. - PMC - PubMed
    1. Schottenfeld D, Beebe Dimmer J, Vigneau F. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol. 2009;19:58–69. - PMC - PubMed
    1. Bojesen R, Andersson M, Riis L, et al. Incidence of phenotypes of and survival from small bowel cancer in Denmark, 1994–2010: a population-based study. J Gastroenterol. 2016;51:891–899. - PubMed
    1. Legué L, Bernards N, Gerritse S, et al. Trends in incidence, treatment, and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in the Netherlands. Acta Oncol. 2016;55:1183–1189. - PubMed

Publication types